Start Date
November 18, 2020
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Selinexor
Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
Rituximab
Dose: 375 mg/m\^2
Bendamustine
Dose: 90 mg/m\^2
Polatuzumab Vedotin
Dose: 1.8 mg/kg
Ibrutinib
Dose: 420, 560 mg
Lenalidomide
Dose: 20, 25 mg
Tafasitamab
Dose: 12 mg/kg
Venetoclax
Dose: 200, 400, 600, 800 mg
Gemcitabine
Dose: 1000 mg/m\^2
Oxaliplatin
Dose: 100 mg/m\^2
Roswell Park Comprehensive Cancer Center, Buffalo
UPMC Hillman Cancer Center, Pittsburgh
US Oncology - Prisma Health, Greenville
Karmanos Cancer Institute, Detroit
University of Michigan Health System, Ann Arbor
Mission Cancer + Blood, Des Moines
Loyola University Medical Center, Maywood
University of Nebraska Medical Center, Omaha
University of Texas Southwestern, Dallas
Baylor Clinic - Mcnair Center, Houston
US Oncology - Texas Oncology Austin Midtown, Austin
US Oncology - Rocky Mountain Cancer Center, Aurora
University of Arizona, Tucson
California Cancer Associates for Research and Excellence, Encinitas
UC San Diego Moores Cancer Center, La Jolla
University of California Irvine, Orange
US Oncology - Oncology Associates of Oregon, Eugene
US Oncology - Northwest Cancer Specialists, Vancouver
Lead Sponsor
Karyopharm Therapeutics Inc
INDUSTRY